REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio gross margin
Gross margin is gross profit as a percentage of revenue.
Regenxbio's gross margin for the twelve months ending Dec 31, 2024 was 59.7%. For fiscal 2024 it was 59.7%, against 58.8% the year before. The highest annual figure on record is 98.7% in fiscal 2015.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | 59.7% | +1.0 |
| FY2023 | Dec 31, 2023 | 58.8% | +7.2 |
| FY2022 | Dec 31, 2022 | 51.6% | −37.4 |
| FY2021 | Dec 31, 2021 | 89.0% | +12.1 |
| FY2020 | Dec 31, 2020 | 76.9% | +0.3 |
| FY2019 | Dec 31, 2019 | 76.6% | −19.0 |
| FY2018 | Dec 31, 2018 | 95.6% | +12.0 |
| FY2017 | Dec 31, 2017 | 83.6% | −14.3 |
| FY2016 | Dec 31, 2016 | 97.9% | −0.8 |
| FY2015 | Dec 31, 2015 | 98.7% | +0.7 |
| FY2014 | Dec 31, 2014 | 98.0% | +0.8 |
| FY2013 | Dec 31, 2013 | 97.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2024 | Dec 31, 2024 | 70.2% | +20.8 |
| Q3 FY2024 | Sep 30, 2024 | 48.8% | −8.3 |
| Q2 FY2024 | Jun 30, 2024 | 52.5% | −0.0 |
| Q1 FY2024 | Mar 31, 2024 | 72.6% | −5.9 |
| Q4 FY2023 | Dec 31, 2023 | 49.4% | −9.8 |
| Q3 FY2023 | Sep 30, 2023 | 57.2% | +6.5 |
| Q2 FY2023 | Jun 30, 2023 | 52.6% | −7.8 |
| Q1 FY2023 | Mar 31, 2023 | 78.5% | +49.3 |
| Q4 FY2022 | Dec 31, 2022 | 59.2% | −35.0 |
| Q3 FY2022 | Sep 30, 2022 | 50.6% | −3.6 |
| Q2 FY2022 | Jun 30, 2022 | 60.3% | +4.9 |
| Q1 FY2022 | Mar 31, 2022 | 29.3% | −45.1 |
| Q4 FY2021 | Dec 31, 2021 | 94.2% | +42.0 |
| Q3 FY2021 | Sep 30, 2021 | 54.2% | −28.3 |
| Q2 FY2021 | Jun 30, 2021 | 55.4% | −16.3 |
| Q1 FY2021 | Mar 31, 2021 | 74.3% | −6.4 |
| Q4 FY2020 | Dec 31, 2020 | 52.2% | −15.6 |
| Q3 FY2020 | Sep 30, 2020 | 82.4% | −0.6 |
| Q2 FY2020 | Jun 30, 2020 | 71.7% | −3.8 |
| Q1 FY2020 | Mar 31, 2020 | 80.7% | −16.0 |
| Q4 FY2019 | Dec 31, 2019 | 67.8% | −25.2 |
| Q3 FY2019 | Sep 30, 2019 | 83.0% | −7.2 |
| Q2 FY2019 | Jun 30, 2019 | 75.5% | −14.8 |
| Q1 FY2019 | Mar 31, 2019 | 96.7% | −1.5 |
| Q4 FY2018 | Dec 31, 2018 | 93.0% | +76.5 |
| Q3 FY2018 | Sep 30, 2018 | 90.3% | −9.7 |
| Q2 FY2018 | Jun 30, 2018 | 90.3% | −9.6 |
| Q1 FY2018 | Mar 31, 2018 | 98.2% | +15.8 |
| Q4 FY2017 | Dec 31, 2017 | 16.5% | – |
| Q3 FY2017 | Sep 30, 2017 | 100.0% | – |
| Q2 FY2017 | Jun 30, 2017 | 99.9% | – |
| Q3 FY2016 | Sep 30, 2016 | 82.4% | – |
See a number that looks wrong?